Thirty-two percent of cases (50/156) were scored with a Her2 Dako score of 3+, 33% (51/156) with a Dako score of 2+, whereas only 2% of CIS specimens (3/156) exhibited positivity for CK5/6 and 1% (2/156) for CK14. This evidence concerns the gene KRT5 and in situ carcinoma.